Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Pluristem Therapeutics Announces First Patient Enrollment In Phase I Clinical Trial For Treatment Of Peripheral Artery Disease With PLX-PAD
Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that the first patient has been enrolled in a Phase I clinical trial of the Company"s allogeneic placental-derived adherent stromal cell product, termed PLX-PAD. PLX-PAD is being used in patients afflicted with critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD). The first patient was enrolled at the Franziskus-Krankenhaus Hospital, Berlin. The initiation of this study follows the recent approval of the Company"s Clinical Trial Application (CTA) to begin clinical trials with PLX-PAD by the Paul Ehrlich Institute (PEI), the German competent authority in the European Union. The Phase I study is designed to evaluate the safety of PLX-PAD in patients with CLI. A total of up to fifteen adults with the disease will be included in the trial which is being conducted at the Franziskus-Krankenhaus Hospital and Charitç© - Universitç¤tsmedizin Hospital, Berlin.
generic viagra online
Study Finds That Tobacco Companies Changed Design Of Cigarettes Without Alerting Smokers
As President Obama prepares to sign a bill giving the Food and Drug Administration (FDA) oversight of the tobacco industry, a new study from Harvard School of Public Health (HSPH) researchers shows that tobacco manufacturers have continually changed the ingredients and the design of their cigarettes over time, even if those changes have exceeded acceptable product variance guidelines. The result, say the researchers, is that consumers who buy the same brand of product are not made aware of how that product has been altered and what effect those alterations might have on their levels of addiction or harm.
News of the day
Health Activists Protest The Absence Of Single Payer To Foment Baucus And The Senate's Silence
On May 13, health care professionals and health care activists gathered on Capitol Hill to demonstrate their support for Senator John Conyer"s HR 676.
Endocrinology

Genome Sequencing Of Schistosomiasis Parasites Could Promote Drug Development

Researchers have sequenced the genomes of two parasites that cause bilharzia or schistosomiasis - a disease transmitted by water-borne snails that affects more than 200 million people worldwide - "revealing potential weaknesses that could be exploited by drug developers," Nature reports (Smith, 7/15). The study, which was published on Wednesday in the journal Nature, was conducted by two international teams of scientists that identified the genetic chemical sequences of two of the five harmful species of the parasite, S. mansoni and S. japonicum, Press Association/Google.com reports (7/15). Researchers found that S. masoni, "the most widespread of the schistomiasis parasites," is comprised of almost 12,000 genes - "about 10 times the size of the malaria parasite genome," according to the BBC. The analysis also found that S. mansoni does not have "a key enzyme needed to make essential fats, and must rely on its host to provide these - revealing a potential Achilles" heel" that could be used to create new drugs, the BBC writes (7/16). The study "explores cost effective ways to develop new therapies, such as the possibility that existing pharmaceutical drugs might be used to target schistosomiasis," according to a University of Maryland press release (7/15). The drug praziquantel, which is "cheap" and "effective," is currently used to treat the disease, but the concern has been that it "does not prevent people from getting re-infected by bathing in infested waters, and reinfection offers plenty of opportunities for the parasite to become resistant," according to AFP/Yahoo! News. Anthony Fauci - director of U.S. National Institute of Allergy and Infectious Diseases, which funded a portion of the research - said, "Chronic infection with schistosoma parasites makes life miserable for millions of people in tropical countries around the globe." He added, "New drugs and other interventions are badly needed" (7/15). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009